Polycystic kidney disease and therapeutic approaches

BMB Reports

Volumn 44, Issue 6, 2011, Pages 359-358

  Park, Eun Young ^a   Woo, Yu Mi ^a   Park, Jong Hoon ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

Drug development; Epigenetic; HDAC inhibitor; miRNA; Polycystic kidney disease

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; GENETIC EPIGENESIS; GENETICS; HUMAN; KIDNEY POLYCYSTIC DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SHORT SURVEY;

ANIMALS; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MICRORNAS; POLYCYSTIC KIDNEY DISEASES; PPAR GAMMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960105492     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2011.44.6.359     Document Type: Short Survey

References (106)

1. Igarashi, P. and Somlo, S. (2002) Genetics and pathogenesis of polycystic kidney disease. J. Am. Soc. Nephrol. 13, 2384-2398.
2. Torres, V. E. and Harris, P. C. (2009) Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 76, 149-168.
3. Watnick, T. and Germino, G. (2003) From cilia to cyst. Nat. Genet. 34, 355-356.
4. Nauli, S. M., Alenghat, F. J., Luo, Y., Williams, E., Vassilev, P., Li, X., Elia, A. E., Lu, W., Brown, E. M., Quinn, S. J., Ingber, D. E. and Zhou, J. (2003) Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat. Genet. 33, 129-137.
5. Belibi, F. A. and Edelstein, C. L. (2010) Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert. Opin. Investig. Drugs 19, 315-328.
6. Shillingford, J. M., Murcia, N. S., Larson, C. H., Low, S. H., Hedgepeth, R., Brown, N., Flask, C. A., Novick, A. C., Goldfarb, D. A., Kramer-Zucker, A., Walz, G., Piontek, K. B., Germino, G. G. and Weimbs, T. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. U. S. A. 103, 5466-5471.
7. Gao, X., Zhang, Y., Arrazola, P., Hino, O., Kobayashi, T., Yeung, R. S., Ru, B. and Pan, D. (2002) Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4, 699-704.
8. Distefano, G., Boca, M., Rowe, I., Wodarczyk, C., Ma, L., Piontek, K. B., Germino, G. G., Pandolfi, P. P. and Boletta, A. (2009) Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol. Cell Biol. 29, 2359-2371.
9. Zafar, I., Belibi, F. A., He, Z. and Edelstein, C. L. (2009) Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol. Dial Transplant 24, 2349-2353.
10. Yamaguchi, T., Hempson, S. J., Reif, G. A., Hedge, A. M. and Wallace, D. P. (2006) Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J. Am. Soc. Nephrol. 17, 178-187.
11. Yamaguchi, T., Reif, G. A., Calvet, J. P. and Wallace, D. P. (2010) Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am. J. Physiol. Renal. Physiol. 299, F944-951.
12. Sas, K. M. (2010) Targeting B-Raf as a treatment strategy for polycystic kidney disease. Am. J Physiol. Renal. Physiol. 299, F942-943.
13. Takiar, V., Nishio, S., Seo-Mayer, P., King, J. D., Jr., Li, H., Zhang, L., Karihaloo, A., Hallows, K. R., Somlo, S. and Caplan, M. J. (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl. Acad. Sci. U. S. A. 108, 2462-2467.
14. Harris, P. C. and Torres, V. E. (2009) Polycystic kidney disease. Annu. Rev. Med. 60, 321-337.
15. Taby, R. and Issa, J. P. (2010) Cancer epigenetics. CA. Cancer J. Clin. 60, 376-392.
16. Felsenfeld, G. and Groudine, M. (2003) Controlling the double helix. Nature 421, 448-453.
17. Strahl, B. D. and Allis, C. D. (2000) The language of covalent histone modifications. Nature 403, 41-45.
18. Tsankova, N., Renthal, W., Kumar, A. and Nestler, E. J. (2007) Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8, 355-367.
19. Pasquinelli, A. E., Reinhart, B. J., Slack, F., Martindale, M. Q., Kuroda, M. I., Maller, B., Hayward, D. C., Ball, E. E., Degnan, B., Muller, P., Spring, J., Srinivasan, A., Fishman, M., Finnerty, J., Corbo, J., Levine, M., Leahy, P., Davidson, E. and Ruvkun, G. (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408, 86-89.
20. Filipowicz, W., Bhattacharyya, S. N. and Sonenberg, N. (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102-114.
21. Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P. and Burge, C. B. (2003) Prediction of mammalian microRNA targets. Cell 115, 787-798.
22. Friedman, R. C., Farh, K. K., Burge, C. B. and Bartel, D. P. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19, 92-105.
23. Calin, G. A. and Croce, C. M. (2006) MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866.
24. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, R. L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negrini, M., Harris, C. C. and Croce, C. M. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 103, 2257-2261.
25. Kato, M., Arce, L. and Natarajan, R. (2009) MicroRNAs and their role in progressive kidney diseases. Clin. J. Am. Soc. Nephrol. 4, 1255-1266.
26. Saal, S. and Harvey, S. J. (2009) MicroRNAs and the kidney: coming of age. Curr. Opin. Nephrol. Hypertens 18, 317-323.
27. Li, X. (2010) Epigenetics and autosomal dominant polycystic kidney disease. Biochim. Biophys. Acta. [Epub ahead of print].
28. Vasyutina, E. and Treier, M. (2010) Molecular mechanisms in renal degenerative disease. Semin. Cell Dev. Biol. 21, 831-837.
29. Karolina, D. S., Wintour, E. M., Bertram, J. and Jeyaseelan, K. (2010) Riboregulators in kidney development and function. Biochimie. 92, 217-225.
30. Kliewer, S. A., Lehmann, J. M., Milburn, M. V. and Willson, T. M. (1999) The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog. Horm. Res. 54, 345-367; discussion 367-348.
31. Liu, Y., Dai, B., Fu, L., Jia, J. and Mei, C. (2010) Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells. Basic Clin. Pharmacol. Toxicol. 106, 523-530.
32. Muto, S., Aiba, A., Saito, Y., Nakao, K., Nakamura, K., Tomita, K., Kitamura, T., Kurabayashi, M., Nagai, R., Higashihara, E., Harris, P. C., Katsuki, M. and Horie, S. (2002) Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum. Mol. Genet. 11, 1731-1742.
33. Dai, B., Liu, Y., Mei, C., Fu, L., Xiong, X., Zhang, Y., Shen, X. and Hua, Z. (2010) Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clin. Sci. (Lond) 119, 323-333.
34. Raphael, K. L., Strait, K. A., Stricklett, P. K., Baird, B. C., Piontek, K., Germino, G. G. and Kohan, D. E. (2009) Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease. Am. J. Nephrol. 30, 468-473.
35. Xu, N., Glockner, J. F., Rossetti, S., Babovich-Vuksanovic, D., Harris, P. C. and Torres, V. E. (2006) Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. J. Nephrol. 19, 529-534.
36. Guan, Y. and Breyer, M. D. (2001) Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 60, 14-30.
37. Liu, M., Fu, L., Liu, C., Xiong, X., Gao, X., Xiao, M., Cai, H., Hu, H., Wang, X. and Mei, C. (2010) DH9, a novel PPARgamma agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of beta-catenin signaling. Invest. New Drugs 28, 783-790.
38. Balkwill, F. (2009) Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361-371.
39. Gardner, K. D., Jr., Burnside, J. S., Elzinga, L. W. and Locksley, R. M. (1991) Cytokines in fluids from polycystic kidneys. Kidney Int. 39, 718-724.
40. Merta, M., Tesar, V., Zima, T., Jirsa, M., Rysava, R. and Zabka, J. (1997) Cytokine profile in autosomal dominant polycystic kidney disease. Biochem. Mol. Biol. Int. 41, 619-624.
41. Li, X., Magenheimer, B. S., Xia, S., Johnson, T., Wallace, D. P., Calvet, J. P. and Li, R. (2008) A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat. Med. 14, 863-868.
42. Pirson, Y. (2008) Does TNF-alpha enhance cystogenesis in ADPKD? Nephrol. Dial Transplant. 23, 3773-3775.
43. Bukanov, N. O., Smith, L. A., Klinger, K. W., Ledbetter, S. R. and Ibraghimov-Beskrovnaya, O. (2006) Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444, 949-952.
44. McClue, S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., Zhelev, N., Zheleva, D. and Lane, D. P. (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 102, 463-468.
45. Park, J. Y., Park, S. H. and Weiss, R. H. (2009) Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease. Am. J. Nephrol. 29, 509-515.
46. Ibraghimov-Beskrovnaya, O. (2007) Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle 6, 776-779.
47. Moreno, S., Ibraghimov-Beskrovnaya, O. and Bukanov, N. O. (2008) Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD. Cell Cycle 7, 1856-1864.
48. Bello-Reuss, E., Holubec, K. and Rajaraman, S. (2001) Angiogenesis in autosomal-dominant polycystic kidney disease. Kidney Int. 60, 37-45.
49. Klagsbrun, M. and Moses, M. A. (1999) Molecular angiogenesis. Chem. Biol. 6, R217-224.
50. Tao, Y., Kim, J., Yin, Y., Zafar, I., Falk, S., He, Z., Faubel, S., Schrier, R. W. and Edelstein, C. L. (2007) VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int. 72, 1358-1366.
51. Amura, C. R., Brodsky, K. S., Groff, R., Gattone, V. H., Voelkel, N. F. and Doctor, R. B. (2007) VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice. Am. J. Physiol. Cell Physiol. 293, C419-428.
52. McGrath-Morrow, S., Cho, C., Molls, R., Burne-Taney, M., Haas, M., Hicklin, D. J., Tuder, R. and Rabb, H. (2006) VEGF receptor 2 blockade leads to renal cyst formation in mice. Kidney Int. 69, 1741-1748.
53. Bernhardt, W. M., Wiesener, M. S., Weidemann, A., Schmitt, R., Weichert, W., Lechler, P., Campean, V., Ong, A. C., Willam, C., Gretz, N. and Eckardt, K. U. (2007) Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am. J. Pathol. 170, 830-842.
54. Gao, J., Zhou, H., Lei, T., Zhou, L., Li, W., Li, X. and Yang, B. (2011) Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur. J. Pharmacol. 654, 92-99.
55. Leonhard, W. N., van der Wal, A., Novalic, Z., Kunnen, S. J., Gansevoort, R. T., Breuning, M. H., de Heer, E. and Peters, D. J. (2011) Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am. J. Physiol. Renal Physiol. 300, F1193-1202.
56. Leuenroth, S. J., Okuhara, D., Shotwell, J. D., Markowitz, G. S., Yu, Z., Somlo, S. and Crews, C. M. (2007) Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc. Natl. Acad. Sci. U. S. A. 104, 4389-4394.
57. Natoli, T. A., Smith, L. A., Rogers, K. A., Wang, B., Komarnitsky, S., Budman, Y., Belenky, A., Bukanov, N. O., Dackowski, W. R., Husson, H., Russo, R. J., Shayman, J. A., Ledbetter, S. R., Leonard, J. P. and Ibraghimov-Beskrovnaya, O. (2010) Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat. Med. 16, 788-792.
58. Chatterjee, S., Shi, W. Y., Wilson, P. and Mazumdar, A. (1996) Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J. Lipid Res. 37, 1334-1344.
59. Yoo, C. B. and Jones, P. A. (2006) Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5, 37-50.
60. Mutskov, V. and Felsenfeld, G. (2004) Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J. 23, 138-149.
61. Taplick, J., Kurtev, V., Kroboth, K., Posch, M., Lechner, T. and Seiser, C. (2001) Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. J. Mol. Biol. 308, 27-38.
62. Taunton, J., Hassig, C. A. and Schreiber, S. L. (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408-411.
63. Bertos, N. R., Wang, A. H. and Yang, X. J. (2001) Class II histone deacetylases: structure, function, and regulation. Biochem. Cell Biol. 79, 243-252.
64. Deribe, Y. L., Wild, P., Chandrashaker, A., Curak, J., Schmidt, M. H., Kalaidzidis, Y., Milutinovic, N., Kratchmarova, I., Buerkle, L., Fetchko, M. J., Schmidt, P., Kittanakom, S., Brown, K. R., Jurisica, I., Blagoev, B., Zerial, M., Stagljar, I. and Dikic, I. (2009) Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci. Signal 2, ra84.
65. Valenzuela-Fernandez, A., Cabrero, J. R., Serrador, J. M. and Sanchez-Madrid, F. (2008) HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 18, 291-297.
66. Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., Seto, E. and Bhalla, K. (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729-26734.
67. Van Bodegom, D., Saifudeen, Z., Dipp, S., Puri, S., Magenheimer, B. S., Calvet, J. P. and El-Dahr, S. S. (2006) The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression. J. Biol. Chem. 281, 31234-31244.
68. Cao, Y., Semanchik, N., Lee, S. H., Somlo, S., Barbano, P. E., Coifman, R. and Sun, Z. (2009) Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proc. Natl. Acad. Sci. U. S. A. 106, 21819-21824.
69. van Bodegom, D., Roessingh, W., Pridjian, A. and El Dahr, S. S. (2010) Mechanisms of p53-mediated repression of the human polycystic kidney disease-1 promoter. Biochim. Biophys. Acta. 1799, 502-509.
70. Nishio, S., Hatano, M., Nagata, M., Horie, S., Koike, T., Tokuhisa, T. and Mochizuki, T. (2005) Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J. Clin. Invest. 115, 910-918.
71. McKinsey, T. A., Zhang, C. L. and Olson, E. N. (2002) MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 27, 40-47.
72. Xia, S., Li, X., Johnson, T., Seidel, C., Wallace, D. P. and Li, R. (2010) Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. Development 137, 1075-1084.
73. Pugacheva, E. N., Jablonski, S. A., Hartman, T. R., Henske, E. P. and Golemis, E. A. (2007) HEF1-dependent Aurora A activation induces disassembly of the primary cilium. Cell 129, 1351-1363.
74. Song, X., Di Giovanni, V., He, N., Wang, K., Ingram, A., Rosenblum, N. D. and Pei, Y. (2009) Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum. Mol. Genet. 18, 2328-2343.
75. Bieliauskas, A. V. and Pflum, M. K. (2008) Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev. 37, 1402-1413.
76. Mehnert, J. M. and Kelly, W. K. (2007) Histone deacetylase inhibitors: biology and mechanism of action. Cancer J. 13, 23-29.
77. Qian, F., Watnick, T. J., Onuchic, L. F. and Germino, G. G. (1996) The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87, 979-987.
78. Ambros, V., Bartel, B., Bartel, D. P., Burge, C. B., Carrington, J. C., Chen, X., Dreyfuss, G., Eddy, S. R., Griffiths-Jones, S., Marshall, M., Matzke, M., Ruvkun, G. and Tuschl, T. (2003) A uniform system for microRNA annotation. RNA 9, 277-279.
79. Kim, V. N. (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6, 376-385.
80. Gregory, R. I., Chendrimada, T. P., Cooch, N. and Shiekhattar, R. (2005) Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123, 631-640.
81. Tijsterman, M. and Plasterk, R. H. (2004) Dicers at RISC; the mechanism of RNAi. Cell 117, 1-3.
82. Rodriguez, A., Griffiths-Jones, S., Ashurst, J. L. and Bradley, A. (2004) Identification of mammalian microRNA host genes and transcription units. Genome Res. 14, 1902-1910.
83. Altuvia, Y., Landgraf, P., Lithwick, G., Elefant, N., Pfeffer, S., Aravin, A., Brownstein, M. J., Tuschl, T. and Margalit, H. (2005) Clustering and conservation patterns of human microRNAs. Nucleic Acids Res. 33, 2697-2706.
84. Liang, M., Liu, Y., Mladinov, D., Cowley, A. W., Jr., Trivedi, H., Fang, Y., Xu, X., Ding, X. and Tian, Z. (2009) MicroRNA: a new frontier in kidney and blood pressure research. Am. J. Physiol. Renal Physiol. 297, F553-558.
85. Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., Lin, C., Socci, N. D., Hermida, L., Fulci, V., Chiaretti, S., Foa, R., Schliwka, J., Fuchs, U., Novosel, A., Muller, R. U., Schermer, B., Bissels, U., Inman, J., Phan, Q., Chien, M., Weir, D. B., Choksi, R., De Vita, G., Frezzetti, D., Trompeter, H. I., Hornung, V., Teng, G., Hartmann, G., Palkovits, M., Di Lauro, R., Wernet, P., Macino, G., Rogler, C. E., Nagle, J. W., Ju, J., Papavasiliou, F. N., Benzing, T., Lichter, P., Tam, W., Brownstein, M. J., Bosio, A., Borkhardt, A., Russo, J. J., Sander, C., Zavolan, M. and Tuschl, T. (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129, 1401-1414.
86. Sun, Y., Koo, S., White, N., Peralta, E., Esau, C., Dean, N. M. and Perera, R. J. (2004) Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 32, e188.
87. Akkina, S. and Becker, B. N. (2011) MicroRNAs in kidney function and disease. Transl. Res. 157, 236-240.
88. Razzaque, M. S., Naito, T. and Taguchi, T. (2001) Protooncogene Ets-1 and the kidney. Nephron. 89, 1-4.
89. Lee, S. O., Masyuk, T., Splinter, P., Banales, J. M., Masyuk, A., Stroope, A. and Larusso, N. (2008) MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J. Clin. Invest. 118, 3714-3724.
90. Pandey, P., Qin, S., Ho, J., Zhou, J. and Kreidberg, J. A. (2011) Systems biology approach to identify transcriptome reprogramming and microRNA targets during the progression of Polycystic Kidney Disease. BMC. Syst. Biol. 5, 56.
91. Tan, Y. C., Blumenfeld, J. and Rennert, H. (2011) Autosomal dominant polycystic kidney disease: Genetics, mutations and microRNAs. Biochim. Biophys. Acta. [Epub ahead of print].
92. Sun, H., Li, Q. W., Lv, X. Y., Ai, J. Z., Yang, Q. T., Duan, J. J., Bian, G. H., Xiao, Y., Wang, Y. D., Zhang, Z., Liu, Y. H., Tan, R. Z., Yang, Y., Wei, Y. Q. and Zhou, Q. (2010) MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation. Mol. Biol. Rep. 37, 2951-2958.
93. Tran, U., Zakin, L., Schweickert, A., Agrawal, R., Doger, R., Blum, M., De Robertis, E. M. and Wessely, O. (2010) The RNA-binding protein bicaudal C regulates polycystin 2 in the kidney by antagonizing miR-17 activity. Development 137, 1107-1116.
94. Chung, A. C., Huang, X. R., Meng, X. and Lan, H. Y. (2010) miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J. Am. Soc. Nephrol. 21, 1317-1325.
95. Kato, M., Zhang, J., Wang, M., Lanting, L., Yuan, H., Rossi, J. J. and Natarajan, R. (2007) MicroRNA-192 in di abetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc. Natl. Acad. Sci. U. S. A. 104, 3432-3437.
96. Krupa, A., Jenkins, R., Luo, D. D., Lewis, A., Phillips, A. and Fraser, D. (2010) Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J. Am. Soc. Nephrol. 21, 438-447.
97. Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y. and Goodall, G. J. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601.
98. Korpal, M., Lee, E. S., Hu, G. and Kang, Y. (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283, 14910-14914.
99. Bracken, C. P., Gregory, P. A., Kolesnikoff, N., Bert, A. G., Wang, J., Shannon, M. F. and Goodall, G. J. (2008) A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 68, 7846-7854.
100. Oba, S., Kumano, S., Suzuki, E., Nishimatsu, H., Takahashi, M., Takamori, H., Kasuya, M., Ogawa, Y., Sato, K., Kimura, K., Homma, Y., Hirata, Y. and Fujita, T. (2010) miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS One 5, e13614.
101. Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., Downing, J. R., Jacks, T., Horvitz, H. R. and Golub, T. R. (2005) MicroRNA expression profiles classify human cancers. Nature 435, 834-838.
102. Bhatt, K., Mi, Q. S. and Dong, Z. (2011) microRNAs in kidneys: biogenesis, regulation, and pathophysiological roles. Am. J. Physiol. Renal Physiol. 300, F602-610.
103. Masyuk, A. I., Huang, B. Q., Ward, C. J., Gradilone, S. A., Banales, J. M., Masyuk, T. V., Radtke, B., Splinter, P. L. and LaRusso, N. F. (2010) Biliary exosomes influence cholangiocyte regulatory mechanisms and proliferation through interaction with primary cilia. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G990-999.
104. Masyuk, T., Masyuk, A. and LaRusso, N. (2009) MicroRNAs in cholangiociliopathies. Cell Cycle 8, 1324-1328.
105. Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M. and Stoffel, M. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689.
106. Esau, C. C. and Monia, B. P. (2007) Therapeutic potential for microRNAs. Adv. Drug Deliv. Rev. 59, 101-114.